异动分析 医疗器械概念+人民币贬值受益+专精特新 1、公司始终致力于将光学技术与医疗器械行业的前沿应用趋势相结合，研究发展高性能的尖端内窥镜 器械产品。目前，公司是国内少有的具备从核心部件、关键设备到系统集成的行业垂直整合能力的企 业。 2、根据2024年年报，公司海外营收占比为69.12%，受益于人民币贬值。 3、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企 业自身的竞争力，以及提升产业链、供应链稳定性和竞争力具有重大意义。公司已入选工信部专精特新 小巨人企业名单。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 来源：新浪证券-红岸工作室 1月7日，海泰新光涨0.77%，成交额1.24亿元，换手率2.29%，总市值54.72亿元。 技术面：筹码平均交易成本为45.92元 该股筹码平均交易成本为45.92元，近期该股获筹码青睐，且集中度渐增；目前股价靠近压力位46.77， 谨防压力位处回调，若突破压力位则可能会开启一波上涨行情。 公司简介 ...

来源：新浪证券-红岸工作室 12月22日，海泰新光跌0.54%，成交额6649.63万元，换手率1.29%，总市值51.26亿元。 异动分析 医疗器械概念+人民币贬值受益+专精特新 1、公司始终致力于将光学技术与医疗器械行业的前沿应用趋势相结合，研究发展高性能的尖端内窥镜 器械产品。目前，公司是国内少有的具备从核心部件、关键设备到系统集成的行业垂直整合能力的企 业。 公司简介 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入-8.29万，占比0%，行业排名52/132，连续3日被主力资金减仓；所属行业主力净流 入-1.26亿，当前无连续增减仓现象，主力趋势不明显。 区间今日近3日近5日近10日近20日主力净流入-8.29万-705.17万-845.92万-874.58万-2451.16万 主力持仓 主力没有控盘，筹码分布非常分散，主力成交额1445.59万，占总成交额的3.89%。 技术面：筹码平均交易成本为46.22元 该股筹码平均交易成本为46.22元，近期筹码减仓，但减仓程度减缓；目前股价靠近支撑位41.58，注意 支撑位处反弹，若跌破支撑位则可 ...

来源：新浪证券-红岸工作室 医疗器械概念+人民币贬值受益+专精特新 1、公司始终致力于将光学技术与医疗器械行业的前沿应用趋势相结合，研究发展高性能的尖端内窥镜 器械产品。目前，公司是国内少有的具备从核心部件、关键设备到系统集成的行业垂直整合能力的企 业。 2、根据2024年年报，公司海外营收占比为69.12%，受益于人民币贬值。 3、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企 业自身的竞争力，以及提升产业链、供应链稳定性和竞争力具有重大意义。公司已入选工信部专精特新 小巨人企业名单。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入-86.66万，占比0.02%，行业排名58/132，该股当前无连续增减仓现象，主力趋势不明 显；所属行业主力净流入-3.47亿，当前无连续增减仓现象，主力趋势不明显。 区间今日近3日近5日近10日近20日主力净流入-86.66万-127.79万-421.43万44.27万-2805.80 ...

12月15日，海泰新光涨1.35%，成交额5588.48万元，换手率1.04%，总市值53.81亿元。 异动分析 来源：新浪证券-红岸工作室 医疗器械概念+人民币贬值受益+专精特新 1、公司始终致力于将光学技术与医疗器械行业的前沿应用趋势相结合，研究发展高性能的尖端内窥镜 器械产品。目前，公司是国内少有的具备从核心部件、关键设备到系统集成的行业垂直整合能力的企 业。 2、根据2024年年报，公司海外营收占比为69.12%，受益于人民币贬值。 3、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企 业自身的竞争力，以及提升产业链、供应链稳定性和竞争力具有重大意义。公司已入选工信部专精特新 小巨人企业名单。 公司简介 资料显示，青岛海泰新光科技股份有限公司位于山东省青岛市崂山区科苑纬四路100号，成立日期2003 年6月11日，上市日期2021年2月26日，公司主营业务涉及医用内窥镜器械和光学产品的研发、生产和销 售。主营业务收入构成为：医用内窥镜器械64.86%，光学产品21.63% ...

2、根据2024年年报，公司海外营收占比为69.12%，受益于人民币贬值。 3、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企 业自身的竞争力，以及提升产业链、供应链稳定性和竞争力具有重大意义。公司已入选工信部专精特新 小巨人企业名单。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 来源：新浪证券-红岸工作室 12月11日，海泰新光跌2.49%，成交额4365.97万元，换手率0.82%，总市值52.47亿元。 异动分析 医疗器械概念+人民币贬值受益+专精特新 1、公司始终致力于将光学技术与医疗器械行业的前沿应用趋势相结合，研究发展高性能的尖端内窥镜 器械产品。目前，公司是国内少有的具备从核心部件、关键设备到系统集成的行业垂直整合能力的企 业。 海泰新光所属申万行业为：医药生物-医疗器械-医疗设备。所属概念板块包括：医疗器械、生物识别、 养老金概念、融资融券、增持回购等。 截至9月30日，海泰新光股东户数5188.00，较上期减少1 ...

出海已成为企业突破增长天花板、构建全球竞争力的必由之路，也成为当下资本市场与产业界共同聚焦的核心热点。 那么，中国企业出海的背后驱动因素有哪些，面临怎样的全球化机遇，在深化全球化布局的过程中面临哪些挑战，又该如何化解风险？ 12月2日，在第一财经联合安永（中国）、矽亚资产管理等专业机构举办的"未来20·2025A股上市公司成长力年会"上，安永大中华区经济咨询服务合伙人余 泠担任主持人，与华明装备（002270.SZ）董事长肖毅，宝光股份（600379.SH）副董事长原瑞涛，海泰新光（688677.SH）副总经理、董秘、财务总监汪方 华，花旗银行（中国）有限公司副行长、商业银行部负责人、董事总经理林海四位嘉宾就上述热点问题展开了深度探讨。 "服务、配件本地化后，就把我们服务和生态根植到客户的心里了，这样才会有生命力。"肖毅说，"走出去"后，要"走进去"，并扎根下去，只有这样才能在 当地真正形成生态圈。 林海也观察到，中国企业布局全球化，已明显从跑马圈地进入到如何扎根共生的阶段，不再是简单把货卖出去、把厂开出去，而是要在不同的土壤里，做品 牌、建立信任和构建生态。 多重因素驱动企业出海 企业出海的核心驱动因素因主 ...

Core Viewpoint - The company, Qindao Haitai New Light Technology Co., Ltd., is focused on integrating optical technology with cutting-edge medical device applications, particularly in high-performance endoscope products, and has a strong vertical integration capability in the industry [2][3]. Company Overview - Qindao Haitai New Light was established on June 11, 2003, and went public on February 26, 2021. Its main business includes the research, development, production, and sales of medical endoscope devices and optical products [7]. - The revenue composition of the company is as follows: medical endoscope devices 64.86%, optical products 21.63%, maintenance services 13.09%, and leasing 0.42% [7]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 448 million yuan, representing a year-on-year growth of 40.47%. The net profit attributable to the parent company was 136 million yuan, with a year-on-year increase of 40.03% [7]. - The company has distributed a total of 277 million yuan in dividends since its A-share listing, with 207 million yuan distributed over the past three years [8]. Market Position and Recognition - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title in China for small and medium-sized enterprises that excel in niche markets and possess strong innovation capabilities [3]. - As of the latest report, 69.12% of the company's revenue comes from overseas markets, benefiting from the depreciation of the Chinese yuan [3]. Stock Performance - On December 4, the stock price of Haitai New Light decreased by 0.04%, with a trading volume of 27.27 million yuan and a turnover rate of 0.50%. The total market capitalization is 5.45 billion yuan [1]. - The average trading cost of the stock is 46.62 yuan, with recent buying activity observed, although the buying pressure is not strong. The stock is currently trading between a resistance level of 46.80 yuan and a support level of 42.48 yuan [6].

Core Viewpoint - The company, Qindao Haitai New Light Technology Co., Ltd., is focused on integrating optical technology with cutting-edge applications in the medical device industry, particularly in high-performance endoscopic instruments [2] Group 1: Company Overview - The company was established on June 11, 2003, and went public on February 26, 2021. Its main business includes the research, development, production, and sales of medical endoscopic instruments and optical products [7] - The revenue composition of the company is as follows: medical endoscopic instruments 64.86%, optical products 21.63%, maintenance services 13.09%, and leasing 0.42% [7] - As of September 30, the company had 5,188 shareholders, a decrease of 1.84% from the previous period, with an average of 23,106 circulating shares per shareholder, an increase of 1.87% [7] Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 448 million yuan, representing a year-on-year growth of 40.47%, and a net profit attributable to shareholders of 136 million yuan, also showing a year-on-year increase of 40.03% [7] - The company has distributed a total of 277 million yuan in dividends since its A-share listing, with 207 million yuan distributed over the past three years [8] Group 3: Market Position and Recognition - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title in China for small and medium-sized enterprises that excel in niche markets and possess strong innovation capabilities [3] - The company benefits from a high overseas revenue proportion of 69.12%, aided by the depreciation of the Chinese yuan [3] Group 4: Technical Analysis - The average trading cost of the company's shares is 46.62 yuan, with recent chip reduction slowing down. The current stock price is near a resistance level of 45.45 yuan, indicating potential for a price correction if this level is not surpassed [6]

来源：新浪证券-红岸工作室 12月1日，海泰新光涨2.02%，成交额7575.18万元，换手率1.40%，总市值54.47亿元。 异动分析 医疗器械概念+人民币贬值受益+专精特新 1、公司始终致力于将光学技术与医疗器械行业的前沿应用趋势相结合，研究发展高性能的尖端内窥镜 器械产品。目前，公司是国内少有的具备从核心部件、关键设备到系统集成的行业垂直整合能力的企 业。 2、根据2024年年报，公司海外营收占比为69.12%，受益于人民币贬值。 3、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企 业自身的竞争力，以及提升产业链、供应链稳定性和竞争力具有重大意义。公司已入选工信部专精特新 小巨人企业名单。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 区间今日近3日近5日近10日近20日主力净流入162.78万-1212.84万-1768.35万-3339.43万-3432.76万 主力持仓 主力轻度控盘，筹码分布较为分散，主力成交额2093.91万 ...

Core Viewpoint - The company, Haitai New Light, is experiencing growth in revenue and profit, benefiting from the depreciation of the RMB and its status as a "specialized, refined, distinctive, and innovative" enterprise in the medical device sector [2][3][7]. Group 1: Company Performance - Haitai New Light's stock price increased by 0.33% on November 27, with a trading volume of 32.64 million yuan and a market capitalization of 5.446 billion yuan [1]. - For the period from January to September 2025, the company achieved a revenue of 448 million yuan, representing a year-on-year growth of 40.47%, and a net profit attributable to shareholders of 136 million yuan, also showing a growth of 40.03% [7]. - The company's revenue from medical endoscope devices accounts for 64.86% of total revenue, while optical products contribute 21.63% [7]. Group 2: Market Position and Recognition - Haitai New Light is recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title in China for companies excelling in niche markets and possessing strong innovation capabilities [3]. - The company has a vertical integration capability in the medical device industry, covering core components, key equipment, and system integration [2]. Group 3: Financial Metrics and Shareholder Information - As of September 30, the company had 5,188 shareholders, a decrease of 1.84% from the previous period, with an average of 23,106 circulating shares per shareholder, an increase of 1.87% [7]. - The company has distributed a total of 277 million yuan in dividends since its A-share listing, with 207 million yuan distributed over the past three years [8]. - Major shareholders include various funds, with the top ten shareholders holding significant stakes, indicating a stable institutional presence [8][9].